|
The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.
|
 |
|
While the injectable retains convenience advantages in dosing frequency, the pill addresses needle aversion and may facilitate broader uptake in primary care settings.
|
|
|
WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.
|
|
|
PsiQuantum will work with the National Cancer Center Japan to develop fault-tolerant algorithms and quantum applications.
|
|
|
The collaboration targets disease areas where conventional small molecule drug discovery has faced challenges.
|
|
